Revenues soar in 1Q for Merge eFilm

Article

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48

PACS vendor Merge eFilm reported a first quarter net sales increase of 41% to $8.64 million compared with $6.12 million in the previous year's quarter ended March 31, 2003. Operating income was $2.14 million, an increase of 45% compared with $1.48 million in the previous year's quarter. Net income was $1.35 million compared with $1.32 million in 1Q 2003. Financial and operational gains reflected increasing popularity of the company's Fusion RIS/PACS. The company closed 17 deals for its Fusion RIS, PACS, or RIS/PACS during the quarter, increasing the total number of Fusion customers to 143, representing more than 290 healthcare facilities. Company executives anticipate continuing positive market conditions, with full-year 2004 guidance of 30% to 35% revenue growth year over year to a range of $37.5 to $39.5 million.

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.